Article
Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behavior.
Inflammatory bowel diseases - 1 Dec 2011
Lichtenstein Gary R, Targan Stephan R, Dubinsky Marla C, Rotter Jerome I, Barken Derren M, Princen Fred, Carroll Susan, Brown Michelle, Stachelski Jordan, Chuang Emil, Landers Carol J, Stempak Joanne M, Singh Sharat, Silverberg Mark S
Abstract excerpt
BACKGROUND: Treatment of Crohn's disease (CD) with biologics may alter disease progression, leading to fewer disease-related complications, but cost and adverse event profiles often limit their effective use. Tools identifying patients at high risk of complications, who would benefit the most from biologics, would be valuable. Previous studies suggest that biomarkers may aid in determining the course of CD. We...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.